

ACKNOWLEDGMENT

*I would like to express my profound gratitude to **Professor Doctor/ Azza Abdel Gawad Tantawy**, Professor of Pediatrics, Faculty of Medicine Ain Shams University for her most valuable advises and support all through the whole work and for dedicating much of her precious time to accomplish this work.*

*I am also grateful to **Professor Doctor/ Moustafa Mohey Ahmady Barakat**, Professor of Pediatrics National Research Centre for his unique effort, considerable help, assistance and knowledge he offered me throughout the performance of this work.*

*I am deeply indebted to **Professor Doctor/ Ahmed Mohammed Aly**, Professor of Virology National Research Centre for his extremely help and support.*

*My appreciation to **Assistant Professor Doctor/ Manal Fuad El shamaa**, Assistant Professor of Pediatrics National Research Centre for her kind help and support.*

*My special thanks and deep obligation to **Doctor/ Amira Abd Al Moneam Adly**, Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University for her continuous encouragement and supervision to continue this work as perfect as I hope it is.*

I am deeply grateful for all the children with cancer and their families for participating in this study. I wish them rapid and complete recovery.

Mohamed Yassin

Background: Intensified chemotherapy increases susceptibility to infections. Respiratory viruses, including respiratory syncytial virus (RSV), parainfluenza virus and Influenza virus A and B are widespread in the community and easily transmitted to patients with hematological malignancy.

Aim of study: to assess the prevalence, risk factors and prognosis of community acquired respiratory viruses in severe lower respiratory tract infections in hospitalized pediatric cancer patients.

Patients and Methods: Ninety children with cancer admitted in the Children's Hospital, Ain Shams University during the period from March 31th, 2007 until September 30th, 2008 suffering from severe lower respiratory tract infections (LRTIs) were included. All were subjected to history and clinical examination; investigations included complete blood picture with differential leucocytic count, erythrocyte sedimentation rate, C - reactive protein and blood culture. Plain chest x-ray and computed chest tomography. A nasopharyngeal swab was examined by multiplex polymerase chain reaction for the following virus genomes: influenza A and B, parainfluenza serotypes 1 and 3 and respiratory syncytial virus. Clinical follow up of patients was done for assessment of clinical outcome.

Results: Hematologic malignancy was the underlying disease in 63.3% (57/90) patients. Forty five % (41/90) were in

remission and 54% (49/90) were in the induction stage. The prevalence of viral infection in the studied patients was 38.5% and 36.3% in patients with hematological and solid tumors respectively ($P=0.83$). The main presenting symptom of LRTI were fever, cough, expectoration and wheezy chest were prominent in 52.9% of patients with viral infection. Thirty two % (29/90) of patients developed respiratory distress in the form of tachypnea and chest retractions, 27% (8/29) of them were positive for viral infection.

Thirty two % (29/90) have positive blood cultures for bacteria (the main pathogen was *Klebsiella*) while 67.7% were negative.

Bacteria were identified as a single cause of LRTI in 17.7% (16/90), viruses in 27% (25/90), fungi in 4.4% (4/90) and mixed causes in 14% (13/90) {6.6% (9/13) mixed viral and bacterial, 4.4% (4/13) mixed bacterial and fungal}.

Nasopharyngeal swabs PCR were positive for viral infection in 34/90 (37.7%) patients, most of them were in May. Influenza virus was the commonest virus detected, being of type A in 16/90 (17%) cases, type B in 4/90 (4.4%) cases followed by Parainfluenza 1 in 9/90 cases (10%), and Parainfluenza 3 in 5 cases (5.5%). RSV was not detected in the studied patients.

Eighty seven patients (96%) were neutropenic 31/87 (35%) of them were positive for viral infection. 27/31 (79.4%) had

severe neutropenia, 3/31 (8.8%) had moderate neutropenia and 1/31 (2.9%) had mild neutropenia.

Seventy % of patients with viral infection had abnormal radiological findings in the form of increased bronchovascular marking in (58.8%), while (20.5%) had either patchy infiltrates or lung collapse in CT.

Eight patients (8.8%) were admitted to the pediatric intensive care unit; 6/8 (75%) for septic shock and disseminated intravascular coagulation and 2/8 for respiratory failure 62.5% had mixed viral and bacterial infections and 3/8 37.5% had mixed bacterial and fungal.

Six patients died during the course of the study (6.6%) from infection related sequelae: 2/6(33%) were having mixed viral and bacterial infections (one had parainfluenza 1 and the other had parainfluenza 3), 4/6 (66%) had mixed bacterial and fungal pathogen.

Conclusions: Respiratory viruses are common pathogens in LRTI, either as a single cause or mixed with bacterial pathogens in pediatric cancer patients. Viral etiology should be suspected with incorporation of antiviral therapy in those patients as there are no specific signs or symptoms. Mixed bacterial and viral infections had the worst prognosis. Rapid diagnostic tests for respiratory viruses should be incorporated in the routine workup

of patients with hematological malignancies as most of patients with viral infection had no specific radiological findings.

Abbreviations:

1. ALL	Acute lymphoblastic leukemia
2. AML	Acute myeloid leukemia
3. ANC	Absolute neutrophilic count
4. BAL	Broncho alveolar lavage
5. BFM	Berlin-Frankfurt-Munich
6. BMF	Bonn-Munich-Frankfurt
7. BMT	Bone marrow transplantation
8. BVM	Bronchovascular markings
9. CBC	Complete blood count
10. CML	Chronic myeloid leukemia
11. CMV	Cytomegalovirus
12. CNS	Central nervous system
13. CRP	C-reactive protein
14. CSF	Cerebro- spinal fluid
15. CT	Computed tomography
16. DIC	Disseminated intravascular coagulopathy
17. FUO	Fever of unknown origin
18. G-CSF	Granulocyte colony stimulating factor
19. GvHD	Graft versus host disease
20. HIV	Human immunodeficiency virus
21. HSCT	Hematopoietic stem cell transplantation
22. HSV	Herpes simplex virus
23. ICU	Intensive care unit
24. IDSA	Infectious Diseases Society of America
25. IFN	Interferon
26. IL	Interleukin

27. INF A	Influenza A virus
28. INF B	Influenza B virus
29. LRTI	Lower respiratory tract infection
30. NHL	Non Hodgkin lymphoma
31. NK	Natural killer cells
32. PCR	Polymerase chain reaction
33. PIF	Parainfluenza virus
34. RD	Respiratory distress
35. RSV	Respiratory syncytial virus
36. RT-PCR	Real-time polymerase chain reaction
37. SARS	Severe acute respiratory syndrome
38. SD	Standard deviation
39. TNF	Tumor necrosis factor
40. VAD	Vascular access device
41. VZV	Varicella zoster virus
42. WBC	White blood cell count

Table of contents:

1. Acknowledgements.....	i
2. Abstract.....	ii
3. Abbreviations.....	vi
4. Table of contents.....	viii
<i>List of tables.....</i>	<i>xii</i>
<i>List of figures.....</i>	<i>xiv</i>
5. Introduction.....	1
6. Objectives of the study.....	4
7. Review of literature.....	5
<i>Acute lymphoblastic leukemia.....</i>	<i>5</i>
<i>Acute myeloid leukemia.....</i>	<i>7</i>
<i>Pathophysiology of Immune Suppression in patients with</i> <i>cancer.....</i>	<i>8</i>
• Impaired Neutrophil Function.....	9
• Impaired Cellular and Humoral Immunity.....	11
• Disruption of Skin and Mucosal Barriers.....	12
• Impaired Reticuloendothelial Function.....	14
• Features known to be associated with a low risk for severe infection.....	15
<i>Febrile infections in children with leukemia.....</i>	<i>16</i>
1-Fever.....	16
2-Immunosuppression induced by treatment.....	17
3-Occurrence of febrile episodes.....	20
4-Etiology, clinical profile and outcome	21
• Respiratory viral infections.....	24
Rhinoviruses.....	27
Respiratory syncytial virus.....	29
Adenovirus.....	31
Parainfluenza virus.....	33
Influenza viruses.....	34

Coronaviruses.....	37
Cytomegalovirus.....	39
• Bacterial infections.....	41
• Fungal infections.....	42
• Treatment and prevention of febrile episodes	44
Algorithm for initial management of febrile neutropenic patients.....	46
Antiviral drug prophylaxis.....	47
Role of granulocyte colony stimulating factor.....	51
<i>Differentiation of viral from bacterial infections in febrile children undergoing chemotherapy for cancer.....</i>	52
<i>Viral Coinfection.....</i>	53
8. Patients and methods.....	54
<i>Patients.....</i>	54
• <i>Inclusion criteria.....</i>	54
• <i>Exclusion criteria.....</i>	54
<i>Study design.....</i>	54
• <i>Complete history taking.....</i>	55
• <i>Clinical examination.....</i>	55
• <i>Investigations.....</i>	56
<i>i. Laboratory.....</i>	56
<i>ii. Radiological.....</i>	57
<i>iii. PCR methodology.....</i>	58
<i>Clinical manifestations suggestive of LRTI.....</i>	62
<i>Radiological findings in case of viral pneumonia.....</i>	63
<i>Statistical Analysis.....</i>	64
9. Results.....	65
• <i>Descriptive demographic data of the studied patients.....</i>	65

• Descriptive laboratory data of the studied patients.....	66
• PCR results for respiratory viral infection.....	67
• Respiratory viral infection in febrile and afebrile patients.....	67
• Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to demographic data.....	68
• Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to clinical data	70
• Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to radiological findings.....	71
• Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to neutropenia and lymphopenia...	73
• Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to antifungal and antiviral treatment.....	74
• Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to morbidity and mortality.....	75
• Seasonal distribution of respiratory viruses detected.....	76
• Different etiologies of LRTI in studied population.....	78
• Patients with mixed viral and bacterial infection admitted to ICU.....	79
• Clinical outcome of studied patients.....	80
• Patients with positive viral infection admitted to ICU had mixed viral and bacterial infections.....	81
• Patients with negative viral infection admitted to ICU had mixed bacterial and fungal infections.....	82

10. Discussion.....	83
11. Summary and conclusions.....	97
12. References.....	99
13. Protocol English.	
14. Protocol Arabic.	
15. Summary Arabic.	

List of tables:

Table 1 Corticosteroid-Induced Effect on Lymphocyte Function.....	12
Table 2 Risk factors for fever and causes of fever in patients with cancer.....	24
Table 3 The most important respiratory viruses.....	26
Table 4 Antivirals used in immunocompromised children.....	48
Table 5 Primers used to detect studied respiratory viruses.....	61
Table 6 World Health Organization Age-Specific Criteria for Tachypnea.....	63
Table 7 Descriptive demographic data of the studied patients.....	65
Table 8 Descriptive laboratory data of the studied patients.....	66
Table 9 Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to demographic data of the studied patients.....	69
Table 10 Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to clinical data.....	70
Table 11 Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to radiological findings.....	71
Table 12 Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to neutropenia and lymphopenia....	73
Table 13 Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to antifungal and antiviral treatment.....	74
Table 14 Comparison between Group I (-ve viral infection) and Group II (+ve viral infection) according to morbidity and mortality.....	75
Table 15 Seasonal distribution of respiratory viruses detected.....	76
Table 16 Patients with mixed viral and bacterial infection admitted to ICU.....	78
Table 17 Patients with positive viral infection admitted to ICU had mixed viral and bacterial infections.....	81
Table 18 Patients with negative viral infection admitted to ICU had mixed bacterial and fungal infections.....	82

List of Figures:

(Figure 1) Algorithm for initial management of febrile neutropenic patients.....	46
(Figure 2) PCR results for respiratory viral infection among studied group.....	67
(Figure 3) Respiratory viral infection in febrile and afebrile patients.....	68
(Figure 4) 9 years old male with CML+ Blastic crisis with viral pneumonia presented with increased BVM and hyperinflation of the lungs and areas of peribronchial thickening.....	72
(Figure 5) 12 years old female with AML under chemotherapy (Adriamycin + Ara C) positive for halo sign.....	72
(Figure 6): Seasonal distribution of respiratory viruses detected.....	77
(Figure 7) Different etiologies of LRTI in studied population.....	78
(Figure 8) Clinical outcome of studied patients.....	80

INTRODUCTION

Cancer is a major disease burden worldwide but there are marked geographical variations in incidence overall and at specific organ sites. Reliable estimation of the number of incidence requires population-based cancer registration. Worldwide, approximately 10 million people are diagnosed with cancer annually and more than 6 million die of the disease every year; currently, over 22 million people in the world are cancer patients. In 2005 cancer killed approximately 42,000 people In Egypt 31,000 of those people were under the age of 70. **(W.H.O., 2007)**

The risk of any child developing acute leukemia is about 1 in 2,000. **(Geaves, 2002)**

Leukemia was a fatal illness until the early 1970s when effective chemotherapy and irradiation were introduced. Since then, the outcome of children with leukemia has improved steadily. Overall survival has increased from 25% to 75% with more intensive therapy and treatment adjusted to specific risk groups. **(Ramanujachar et al., 2006)**

Today, an important goal in improving the outcome of children with leukemia is associated with treatment-related factors. Intensified antileukemia treatment increases susceptibility to infections. Despite effective antimicrobial treatment of infections, they still are the leading cause of treatment-related morbidity and mortality. **(Slats et al., 2005)**

The occurrence of febrile episodes during anticancer treatment varies from 2.6 to 4.2 episodes per patient years at risk. The

microbiologic cause of infection or the focus of infection in children with cancer is found in 30% to 40% of the cases. **(Katsimpardi et al., 2006)**

The incidence of bacteremia varies from 8.5% to 28% in febrile episodes, Depending on the intensity of antileukemia therapy. **(Stabell et al., 2007)**

Mortality due to invasive infections is low, usually less than 10% but varying from 3% to 17%, depending on the immunologic status of the leukemic patient and on the microbiologic causal agent. **(Slats et al., 2005)**

Most septicemias occur in association with neutropenia and are caused by gram-positive bacteria. A considerable number of febrile episodes have remained classified as fever of unknown origin (FUO). Respiratory viruses are the most common cause of infections in children, and they are naturally a potential cause of febrile episodes in children with cancer. Respiratory viral infections in children with cancer have not been as common as would have been expected. **(Rahiala et al., 1998)**

Respiratory syncytial virus (RSV) and parainfluenza viruses have been the most common causative viruses. The most common respiratory virus, rhinovirus, has been searched for only in a few studies. **(Christensen et al., 2005)**

The role of these viruses in immunocompromised children is not yet clear. Prompt and reliable etiologic diagnosis of fever is crucial. It determines the patient's treatment and gives information on the clinical course and outcome of the illness. Unnecessary treatments should be avoided. In addition, economic losses, discomfort to the